New hope for chinese patients with severe transplant complication
NCT ID NCT06462469
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 35 times
Summary
This study tests the drug ruxolitinib in Chinese patients aged 12 and older who have a serious complication after a stem cell transplant called graft-versus-host disease (GvHD) that did not improve with steroids. The goal is to see if ruxolitinib can control the disease by reducing symptoms. About 36 participants will take ruxolitinib pills, and doctors will check their response after 28 and 56 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGGuangzhou, Guangdong, 510000, China
-
Novartis Investigative Site
RECRUITINGGuangzhou, Guangdong, 510515, China
-
Novartis Investigative Site
RECRUITINGZhengzhou, Henan, 450003, China
-
Novartis Investigative Site
RECRUITINGWuhan, Hubei, 430030, China
-
Novartis Investigative Site
RECRUITINGChangchun, Jilin, 130021, China
-
Novartis Investigative Site
RECRUITINGXian, Shanxi, 710061, China
-
Novartis Investigative Site
RECRUITINGChengdu, Sichuan, 610072, China
-
Novartis Investigative Site
RECRUITINGHangzhou, Zhejiang, 310003, China
-
Novartis Investigative Site
RECRUITINGBeijing, 100028, China
-
Novartis Investigative Site
RECRUITINGBeijing, 100034, China
-
Novartis Investigative Site
RECRUITINGBeijing, 100039, China
-
Novartis Investigative Site
RECRUITINGBeijing, 100070, China
-
Novartis Investigative Site
RECRUITINGDalian, 116000, China
-
Novartis Investigative Site
RECRUITINGFuzhou, 350001, China
-
Novartis Investigative Site
RECRUITINGShanghai, 200025, China
-
Novartis Investigative Site
RECRUITINGTaian, 271099, China
-
Novartis Investigative Site
RECRUITINGTianjin, 300020, China
Conditions
Explore the condition pages connected to this study.